MedTrace Logo

A Study of SA030 Injection in Overweight or Obese Participants

NCT07479862 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-03-18

No results posted yet for this study

Summary

This study is the first time SA030 is being given to people. The goal is to understand how safe it is, how well it is tolerated, and how the body processes and responds to a single dose of SA030 in individuals who are overweight or obese.

Over the last few decades, more and more people around the world have become overweight or obese, and the numbers keep rising in almost every country. From 1990 to 2021, this problem grew steadily and reached its highest point in 2021.

Conditions

Interventions

DRUG

Dose escalation of SA030

Single dose, 5 dose levels

DRUG

Matching placebo of SA030

Arm 2. single dose, matching placebo

Sponsors & Collaborators

  • Suzhou Siran Biotechnology Co.,Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-16
Primary Completion
2026-08-18
Completion
2027-03-03

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07479862 on ClinicalTrials.gov